Roche shares knocked by concern over side effects in obesity pill trial
Roche shares fall 3.5%
Early study trial showed high rate of temporary side effects
JP Morgan analysts say heart rate increase is as a concern
Roche plans slower ramp-up of pill dose in next trial
Updates share price in paragraph 2, further details on side effects in pill trial in paragraphs 6 and 8
FRANKFURT, Sept 12 (Reuters) -Shares in Roche ROG.S dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans.
Roche shares were trading 3.5% down by 0940 GMT, the second biggest faller on the pan-European STOXX 600 index .STOXX, after the company presented details on the trial with once-daily pill CT-996 late on Wednesday.
A brief summary in July of the study's promising results had boosted the Swiss drugmaker's share price.
According to a presentation at a meeting of the European Association for the Study of Diabetes in Madrid, all 25 trial participants experienced mild or moderate side effects, or adverse events in industry parlance, including those that only received an ineffective placebo.
Side effects from the pill, part of Roche's $2.7 billion acquisition of Carmot in December, were mostly gastrointestinal (GI), like those associated with similar drugs.
However, it also disclosed a higher heart rate by up to 15 beats per minute, which Roche said was in line with other drugs in the class. Still, JP Morgan analysts said this was a concern because any impact on heart health would become a key differentiator in a competitive market.
The analysts, and their counterparts at Barclays and Jefferies, described the overall number of adverse events as high.
Side effects data that Roche released on Monday on another early Carmot project, injection CT-388, had also weighed on its shares, for a 5.4% decline so far this week.
"Investor excitement for Roche's obesity franchise may now take a pause, in our view, given both acquired assets showed higher-than-anticipated GI side effects," Jefferies analysts said.
SECOND TRIAL PHASE TO START NEXT YEAR
In terms of efficacy, Roche reiterated its statement in July that the once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes.
It said the Phase I trial had followed a convention of ramping up the drug dose, a process known as titration, faster than is planned for later trial stages, in order to quickly uncover any unforeseen side effects.
The frequency of adverse events was "consistent with brisk up-titration and early stage of development", Roche said.
"These data support the continued investigation of CT-996 in studies of longer duration with larger sample sizes and slower titrations," the company said, adding that the second of three trial stages would start next year.
But JP Morgan analysts cautioned that a slower-ramp up in larger trials could make it impossible to replicate the fast weight loss that had impressed markets in July.
"The concerning tolerability profile... may be hard to titrate away without a significant decline in efficacy," they said in a note.
An update on Wednesday by Novo Nordisk NOVOb.CO, a pioneer in the weight-loss market alongside Eli Lilly, saying that its experimental pill was associated with mild-to-moderate side effects, was more favourably received by investors.
Roche also said on Wednesday that the headline result of 6.1% weight loss over four weeks was based on just six patients, underscoring the uncertainty of the development project.
Reporting by Ludwig Burger, editing by Rachel More and Emelia Sithole-Matarise
Asset collegati
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
